Shire PLC (SHPG) Now Covered by FBR & Co

Equities research analysts at FBR & Co began coverage on shares of Shire PLC (NASDAQ:SHPG) in a research note issued to investors on Thursday. The firm set a “buy” rating and a $201.00 price target on the biopharmaceutical company’s stock. FBR & Co’s target price points to a potential upside of 38.38% from the stock’s previous close.

SHPG has been the subject of several other research reports. BidaskClub lowered shares of Shire PLC from a “sell” rating to a “strong sell” rating in a research report on Wednesday, July 19th. Barclays PLC lowered shares of Shire PLC from an “overweight” rating to an “equal weight” rating in a research report on Friday, August 11th. Evercore ISI assumed coverage on shares of Shire PLC in a research report on Wednesday, August 16th. They set an “outperform” rating and a $196.00 price objective for the company. Cantor Fitzgerald set a $222.00 price objective on shares of Shire PLC and gave the company a “buy” rating in a research report on Saturday, July 1st. Finally, Royal Bank Of Canada reiterated a “buy” rating and set a $213.00 price objective on shares of Shire PLC in a research report on Monday, October 2nd. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and fourteen have issued a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $219.25.

Shares of Shire PLC (NASDAQ SHPG) traded down 1.74% during trading on Thursday, reaching $145.25. 1,078,686 shares of the company were exchanged. The stock’s 50 day moving average is $153.97 and its 200 day moving average is $164.18. The company has a market capitalization of $43.26 billion, a price-to-earnings ratio of 64.99 and a beta of 1.63. Shire PLC has a 1-year low of $139.36 and a 1-year high of $192.64.

Shire PLC (NASDAQ:SHPG) last released its quarterly earnings data on Friday, October 27th. The biopharmaceutical company reported $3.37 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $3.66 by ($0.29). Shire PLC had a net margin of 4.70% and a return on equity of 14.10%. Equities analysts anticipate that Shire PLC will post $14.92 earnings per share for the current year.

WARNING: “Shire PLC (SHPG) Now Covered by FBR & Co” was reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this news story on another publication, it was stolen and republished in violation of United States and international trademark and copyright legislation. The correct version of this news story can be viewed at https://ledgergazette.com/2017/10/21/shire-plc-shpg-now-covered-by-fbr-co.html.

A number of hedge funds have recently bought and sold shares of the stock. Inspirion Wealth Advisors LLC increased its stake in Shire PLC by 0.4% in the 2nd quarter. Inspirion Wealth Advisors LLC now owns 1,944 shares of the biopharmaceutical company’s stock worth $321,000 after buying an additional 8 shares during the period. Synovus Financial Corp increased its position in Shire PLC by 0.4% during the 2nd quarter. Synovus Financial Corp now owns 2,780 shares of the biopharmaceutical company’s stock valued at $458,000 after purchasing an additional 11 shares during the period. Baldwin Investment Management LLC increased its position in Shire PLC by 1.4% during the 2nd quarter. Baldwin Investment Management LLC now owns 1,626 shares of the biopharmaceutical company’s stock valued at $269,000 after purchasing an additional 23 shares during the period. Hartford Financial Management Inc. increased its position in Shire PLC by 5.4% during the 2nd quarter. Hartford Financial Management Inc. now owns 621 shares of the biopharmaceutical company’s stock valued at $102,000 after purchasing an additional 32 shares during the period. Finally, American International Group Inc. increased its position in Shire PLC by 1.2% during the 1st quarter. American International Group Inc. now owns 4,607 shares of the biopharmaceutical

SHPG has been the subject of several other research reports. BidaskClub lowered shares of Shire PLC from a “sell” rating to a “strong sell” rating in a research report on Wednesday, July 19th. Barclays PLC lowered shares of Shire PLC from an “overweight” rating to an “equal weight” rating in a research report on Friday, August 11th. Evercore ISI assumed coverage on shares of Shire PLC in a research report on Wednesday, August 16th. They set an “outperform” rating and a $196.00 price objective for the company. Cantor Fitzgerald set a $222.00 price objective on shares of Shire PLC and gave the company a “buy” rating in a research report on Saturday, July 1st. Finally, Royal Bank Of Canada reiterated a “buy” rating and set a $213.00 price objective on shares of Shire PLC in a research report on Monday, October 2nd. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and fourteen have issued a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $219.25.

Shares of Shire PLC (NASDAQ SHPG) traded down 1.74% during trading on Thursday, reaching $145.25. 1,078,686 shares of the company were exchanged. The stock’s 50 day moving average is $153.97 and its 200 day moving average is $164.18. The company has a market capitalization of $43.26 billion, a price-to-earnings ratio of 64.99 and a beta of 1.63. Shire PLC has a 1-year low of $139.36 and a 1-year high of $192.64.

Shire PLC (NASDAQ:SHPG) last released its quarterly earnings data on Friday, October 27th. The biopharmaceutical company reported $3.37 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $3.66 by ($0.29). Shire PLC had a net margin of 4.70% and a return on equity of 14.10%. Equities analysts anticipate that Shire PLC will post $14.92 earnings per share for the current year.

WARNING: “Shire PLC (SHPG) Now Covered by FBR & Co” was reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this news story on another publication, it was stolen and republished in violation of United States and international trademark and copyright legislation. The correct version of this news story can be viewed at https://ledgergazette.com/2017/10/21/shire-plc-shpg-now-covered-by-fbr-co.html.

A number of hedge funds have recently bought and sold shares of the stock. Inspirion Wealth Advisors LLC increased its stake in Shire PLC by 0.4% in the 2nd quarter. Inspirion Wealth Advisors LLC now owns 1,944 shares of the biopharmaceutical company’s stock worth $321,000 after buying an additional 8 shares during the period. Synovus Financial Corp increased its position in Shire PLC by 0.4% during the 2nd quarter. Synovus Financial Corp now owns 2,780 shares of the biopharmaceutical company’s stock valued at $458,000 after purchasing an additional 11 shares during the period. Baldwin Investment Management LLC increased its position in Shire PLC by 1.4% during the 2nd quarter. Baldwin Investment Management LLC now owns 1,626 shares of the biopharmaceutical company’s stock valued at $269,000 after purchasing an additional 23 shares during the period. Hartford Financial Management Inc. increased its position in Shire PLC by 5.4% during the 2nd quarter. Hartford Financial Management Inc. now owns 621 shares of the biopharmaceutical company’s stock valued at $102,000 after purchasing an additional 32 shares during the period. Finally, American International Group Inc. increased its position in Shire PLC by 1.2% during the 1st quarter. American International Group Inc. now owns 4,607 shares of the biopharmaceutical company’s stock valued at $803,000 after purchasing an additional 54 shares during the period. 19.24% of the stock is currently owned by institutional investors.

Shire PLC Company Profile

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.

Analyst Recommendations for Shire PLC (NASDAQ:SHPG)

Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply